Positive Data from First Clinical Study of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor Designed for First Point-of-Contact STEMI Therapy, Presented at AHA 2019 Late-Breaking Science Session

SAN DIEGO–(BUSINESS WIRE)–Data from a completed clinical study show RUC-4 provided a potent, rapid, and sustained platelet inhibition effect in stable CAD patients w/aspirin.